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Introduction
The continuing problem of HIV infection

Back in 1984, when AIDS was first shown to be caused by the human
immunodeficiency virus (HIV) , the world was skeptical that any
successful treatment would ever be found. Since then, much has
been discovered about preventing and slowing the infection process,
and we now have at our disposal more weapons than were ever
thought possible. However, a cure still eludes all research efforts
made in the past 13 years.
AIDS is fast becoming an epidemic in many parts of the
world, with an estimated 30.6 million people infected globally 20 million of whom reside in sub-Saharan Africa. Still, the large
amount of infected individuals is miniscule in comparison to the
high percentage of these people who don't even know that they are
infected [1]. Just this past year, the U.N. Program on HIV / AIDS
estimated that nine out of ten HIV infected people in Africa are
unknowingly harboring the virus and are ignorantly contributing to
the spread of AIDS. Clearly, HIV infection is still one of the major
health concerns of our time and will remain a problem until a readily
available vaccine is developed.
Though the present situation of HIV infection looks grim for
less industrialized countries such as those in Africa, the other side
of the globe is experiencing new hope. Due to concentrated research
and public awareness efforts, the United States has actually experienced a drop in the HIV infected population. The difference here
lies in the availability of medical care, heightened awareness and educational programs, and access to quick and accurate HIV-positive
testing. The sooner these measures can be adopted by underdeveloped countries, the closer we may be to totally eradicating this
harmful virus.
Thanks to research efforts made by scientists in 1996, many
new anti-HIV drugs have been developed, and some are now available by prescription. These chemotherapies, although not a cure,
help delay the onset of the many symptoms of AIDS and prolong
the life of many HIV infected patients. One must be cautious in
the scheduling of this treatment though, since a large variety of side
effects exist for each chemotherapy. These side effects have caused
physicians and medical scientists to be locked in a tug-of-war be2
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tween treating a patient with maximal chemotherapy and administering a mediocre treatment schedule to lessen the detrimental
effects of the drugs.
1.2

Infection Background

HIV belongs to the well known retroviral family, Retroviridae, which
consists of viruses having an unique form of RNA replication. This
replication begins with reverse transcription of virion RNA into a
single strand of cD NA and is catalyzed by the enzyme reverse transcriptase. Synthesis of cDN A involves the concurrent digestion of
the viral RNA with the RNAse portion of the reverse transcriptase.
After the linear double stranded DNA is complete, it is subsequently
circularized, integrated into the host chromosomal DNA, and then
used for transcription of the mRNA (for viral protein translation)
and the full-length genomic RNA (for the newly formed virions) [5].
The host cells which HIV infects are human lymphocytes
known as helper T cells. The helper T cell plays an integral role
in immune response, and without them the human body is severely
handicapped in fighting disease. Many opportunistic conditions can
result if the helper T cell count is low enough, including fungal infections, bacterial infections, and rare forms of cancer. The first step
of infection involves the binding of a virion to a receptor molecule
on the host cell surface. The receptor for HIV, CD4, is a transmembrane protein which normally plays an important role in signaling
between the helper T cells and the antigen presenting cells which
provide antibody n1ediated immunity. Even when a portion of the
CD4 receptor is bound to other cell surface molecules, it retains the
HIV receptor activity and the virus can enter the cell by recognizing
the receptor with its own 'key' molecule, gp120 or surface protein
(SU) [5]. Also, the presence of a specific 'fusion receptor' for HIV
is being invoked to explain the lack of infection of mouse hybrids
expressing the human CD4 protein. Clearly, there must be some
other factor which allows viral entry. This second essential receptor
is known as a chemokine receptor, an example of which is CXCR4

[13] .
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In brief, the replication cycle followed by HIV consists of the
following steps [5]:
1) Attachment of the virion to the specific receptor on the host
cell surface.
2) Penetration of the virion core into the cell.
3) Reverse transcription to copy viral genome RNA into DNA
which can be inserted into the host.
4) Transportation of the DNA to the nucleus.
5) Integration of the viral DNA into random sites in cell DNA to
form the provirus.
6) Synthesis of viral RNA by cellular RNA polymerase II using
the integrated provirus as the template.
7) Post-transcriptional processing of RNA to form genome and
mRNAs.
8) Virion protein synthesis (translation of viral mRNAs).
9) Assembly and budding of new virions.
10) Proteolytic processing of capsid proteins via the viral protease
enzyme.
Since the HIV life cycle is quite different from any other cell
in the human body, many antiretroviral treatments are available
which take advantage of its uniqueness. AZT, for example, is a
drug which inhibits the viral enzyme reverse transcriptase. AZT
and other types of retroviral chemotherapy are collectively referred
to as anti-HIV therapies. This designation includes any treatment
which specifically stops HIV from reproducing or infecting its primary target, the helper T cells. It is conceivable that any of the
above steps may be inhibited by a certain treatment, but as of now
there are three main catagories of drugs available.
The three basic types of anti-HIV chemotherapy currently
available by prescription or through experimental trials are nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors. All of these agents limit
HIV infection for some amount of time, but since the virus is highly
mutagenic it eventually develops resistance, and the treatment soon
becomes useless. Many experts believe that using combination or
'cocktail' chemotherapy - two or more drugs administered simultaneously - may help slow the development of resistance by HIV and
also act more efficiently in inhibiting viral reproduction.
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1.3

An optimal control of HIV infection

The main thrust of this investigation is to suggest an optimal method
of treating HIV infection given the known facts about the infection
process. Many mathematical models already exist describing HIV
infection, and we propose using one of these models to monitor the
progression of HIV infection in a patient. Of the many chemotherapies available, an experimental chemokine derivative was first chosen
to prevent the virus from entering a T cell (13]. Recently, combination therapy has been applied to our study with an additional viral
protease inhibitor.
While ant i- HIV chemotherapy has been used for some time,
an optimal treatment schedule has been at best a rough approximation. Until a cure is found, the primary problem faced by physicians today is one of balance. Their objective is to inhibit the
virus as much as possible while simultaneously holding the side
effects of treatment to a minimum. This must be done by an
'optimal' chemotherapy schedule - one which both maximizes patient's uninfected T cells, and minimizes any harmful effects that
the chemotherapy might incur. Through mathenlatical modeling
and optimal control theory, we propose an optimal treatment strategy to strike a balance between the two effects.
Our analysis begins with a description of the mathematical
model used and then compares this model with others adopted by
medical researchers today. Optimal control theory will then be applied to the model, and methods for solving our problem will be
explained. Once our problem is set up, numerical methods will then
be used to generate the resultant optimal treatment schedule for
an HIV infected patient. A discussion of the results and potential
future applications will follow thereafter.
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2

Mathematically Modeling HIV Infection

In the recent past, many mathematical models for the treatment of
HIV infection have been developed [9], [11], [14], and [15]. An overwhelmingly similar aspect of these models is their use of first order
ordinary differential equations (ODE's) describing the interaction
between the viral particles and the T cells. In each model, the T
cells are assumed to express the CD4 and CXCR4 protein receptors
on their surface and any others found in the future to be central to
HIV entry [13J. This just means that for the modeled helper T cells,
all of the requirements for HIV entry are met, and each helper T cell
has an equal probability of being infected. Also notice that any other
cell expressing the receptor can also be infected by HIV. This is how
HIV 'hides out' in areas of the brain protected from chemotherapies
by the blood-brain barrier [18J. In the model which was used, we
assumed that these secondary infection sites play such a small role
in the infection process that they may be neglected. However, some
models take these other sites into account, and we will go over an
example of this later in the section. For now, the model which was
used in our analysis will be presented and explained.
2.1

Our Model

In order to begin the optimal control procedure, it is necessary to
obtain a model which describes the basic interaction between HIV
and the immune system's T cells. In [14] and [16], a model is given
which simulates the infected scenario. We utilize this model and recommend that the reader see these papers for a complete derivation
and verification. A brief discussion is presented below.
The model consists of four states, three of which are T cell
categories and another represents the HIV virus. We let T(t) represent the concentration (number of T cells per mm3 ) of uninfected T
cells at time t, and T*(t) and T**(t) are used to denote the concentrations of latently infected and actively infected T cells, respectively
at time t. Latently infected T* cells are those in which HIV has inserted its genetic material, but as of yet no virus is being produced
from the host cell. Actively infected T** cells, as the name implies,
actively produce HIV virions since, unlike T* cells, the viral genetic
information has been 'turned on.' The concentration of free infectious virus at time t will be denoted by V(t) (viral particles which
6

are able to infect and have not already entered a cell). Time t is
measured in days in all equations in the following analysis.
Each of the four states is a function of time and represents
a solution to a first order differential equation describing infection
kinetics. The left hand side of each equation is the first derivative of
the state with respect to time. Hence, this derivative term represents
the rate of growth of each state (in concentration per time) or equivalently, the slope of the state function at each time point. Therefore,
the units on the right hand side of the equation must agree with the
concentration per unit time dimensions, so each major term separated must also have these units. For example, in equation (1) the
second term -J-tTT is actually -J-tT(days)-lT(concentration of T
cells). Notice that the cOlnbination of units yields the desired result
of concentration per unit time. The system of equations describing
HIV infection consists of the following first order ODE's:

(1)

dT -_ rtV
s
T* + T** ) - kl VT,
([[
- J-tTT + rT ( 1 - T + Tmax

(2)

d];* = kl VT - J-tTT* - k2T*,

(3)

dT** ---a;:r-

(4)

~ = N J-tbT** - kl VT - J-tv V.

k2T* -

II. T**
r
b,

• In (1), 1 ~ V is positive and represents the production of new
T cells inversely affected by the amount of virus [3, 10]. The
second term, -J-tTT, models the exponential decay of the T cell
population, with a death rate of -J-tTT. Our third term is the
logistic growth of the T cell population with saturation occuring
at Tmax' In order to see this, notice that when the total T cell
population reaches its maximum, i.e. when T+T*+T** = Tmaxl
the entire term rT ( 1 - T

+ t:~ T")

becomes zero and will

therefore not contribute to the growth of T cells.
The fourth and final term in equation (I), -kl VT, deals with
the interaction between the viral particles. This term is analogous to a second order rate law in enzyme kinetics in that
7

it assumes that both the concentration of T cells, T, and the
virion concentration, V, contribute to the formation of infected
T cells by combining with a rate constant of k1 . Once a T cell
is invaded by the virus, it then becomes a latently infected T*
cell. - kl VT is thus a loss term for healthy T cells in equation
(1), and kl VT is a gain term for T* in equation (2).
• In the ODE (2), the first term kl VT is a growth term for the
population of latently infected cells. Also, these cells have two
separate removal rates. The first, -J-LT, is as before a natural
death rate constant for those T cells not producing virus. The
second death rate constant, -k2' actually represents a transfer
rate for this population into the next state T** described by
equation (3).
• The ODE (3) models the actively infected T cell population.
As stated before, latently infected cells become actively infected
with a rate constant of k2 . The second term -J-LbT** in (3) is a
death rate for the actively infected T cells due to the production
of virus.
• The free virus population is described by our final ODE of the
system, equation (4). We assume that each actively infected
cell produces N viral particles before it dies. Also, whenever
a virion infects a healthy T cell,' the virion itself enters the
cell and is removed from the free virus population. Thus, the
term - kl VT is a loss term for the free viral population, V.
Any interaction of the virus with previously infected T cells
is neglected since these cells soon lose their CD4 protein after
initial infection due to down regulation of transcription by viral
gene products [5]. The last term, -J-Lv V, lumps together viral
loss of infectivity and removal from the body into a common
death rate for the virus.
Analysis of the stability is given in [9] and [16]. This system
was shown to have two steady states, an uninfected steady state and
an endemically infected steady state. The uninfected steady state
occurs when no virus is present, i.e T
To, T* = 0, T** = 0, and
V = 0. The second, endemically infected steady state, occurs with
8

each of the cell populations at positive values. This second type is
analogous to a remission period during the infection process. During
this period, symptoms seemingly disappear from the patient and the
T cell population appears to remain constant. However, the body is
constantly producing T cells, but at this stage there exists a balance
between the body's efforts and the rate of infection by the virus.
Remission is a very delicate stage in any type of infection, and any
perturbance could wildly shift the equilibrium toward problematic
infection.
In fact, Perelson et al. [16] showed that if the parameter
N was below a critical value, Ncritl the uninfected steady state is
stable and the infected steady state is unstable. At N
Ncrit,
The stability is exchanged through a bifurcation and the infected
state becomes locally stable. For N > Ncrit, other bifurcations in
the eigenvalues can occur, and therefore global stability could not
be shown. As an example, it was shown that stability can be lost
for the infected steady state giving rise to stable limit cycles. This
behavior is believed to occur only for parameter values lying outside
of the possible ranges of biological feasibility.
Notice that these equations are coupled and nonlinear. In
order to solve the first ODE, ~I, we must also have information
about V, T*, and T** at each time t. Since these other equations
are described by ODE's, we must solve the entire system at each
time step until we can proceed to the next.

2.2

Other Models

Many other models describing HIV infection exist, and without a
brief summary of the modeling progress we would leave the reader
believing that everything about the modeling of HIV infection has
been said and done. This is hardly the case. The disease course is
far too complicated a process for an easy analysis to be performed.
With the available data and hypothesized mechanisms gaining more
and more support, the interaction between the virus and humans
has been approached in a variety of different ways. Among many
modelers, there is some controversy over which model is the best. We
will discuss a few of these attempts to give the reader a better flavor
of the model development process. Our starting point is a general
model of two ordinary differential equations, and an expansion on
9

this primary model will lead us to an inclusion of variable parameters
and non-lymphatic infection sites.
In [17], the dynamics of cell infection and virion production
are represented by

= kTV -

(5)

dT*
dt

8T*

(6)

dft = N8T* - cV,

'

=

where T*
T* (t) and V
V (t) are the populations of
infected target cells and roaming virus, respectively at time t. The
rate of decay of infected cells is -8T*, and the infection rate is given
by kTV where T is the total population of uninfected T cells and is
assumed constant in the time of treatment, i.e., it does not depend
on time. This is the main difference between this model and our
four-ODE model which accounts for longer intervals of treatment
by assuming T T(t).
In the second ODE, (6), N is the average number of virions
escaping the infected cell before complete cell lysis and is measured
per infected cell per day and per lifetime of an infected cell. In a
short period of time, the system is assumed to be in a steady state
with T*(t) = T* and V(t) = if as constant values. This model, (5)
and (6) is then perturbed by a protease inhibitor which interrupts
viral production by inhibiting correct viral protein processing. The
effect of this treatment is that only noninfectious viral particles escape from the host cell. The differential equations for the perturbed
system are

=

(7)

dT*
dT = kT~

(8)

dV1
dt

(9)

d~rI = N8T* - cVNJ,

8T*,

-c~,

where ~(t) and VN1(t) are the concentrations of infectious
and noninfectious virions, respectively, at the time after chemotherapy begins. Although this model describes the general flow of the
disease progression during a shortened time period, it does not take
into account a change in the daily turnover rates of virus and T cell
10

populations with time. Another model which attempts to do so is
being developed presently by Kirschner and Webb [11].
Kirschner and Webb's version of a predator-prey (LotkaVolterra type) model consists of a two differential equations in the
general form of the equations
(10)

dT*
dT

(11)

dJi- = 6(t)T* -

k(t)TV

8(t)T*,
c(t)V,

where the constant rate parameters have been replaced by
disease-course, time-dependent parameters. The equations (10) and
(11) are identical to equations (5) and (6) except for this assumption
of time dependence, and because of this, equations (10) and (11)
more effectively model the nonlinearities of disease dynamics. Over
the long frame of time that is used to model the effects of treatment
on T cell and viral population, this variable coefficient model should
be a better model. However, the previous model, (5) and (6), may
be needed when modeling faster processes occuring in short period
treatment intervals.
As a final case of HIV infection models, an example using
secondary sources of infection is now presented. These secondary
infection sites may be neurons of the central nervous system or possibly other immune system cells such as macrophages. This model,
by Perelson et al. [15], includes macrophage cells, M(t), in addition
to T cells, T(t). Both uninfected cell types serve as hosts to the
virus, V(t). Also, actively infected T cells are represented by T*(t)
while latently infected T cells are represented by L(t). Notice that
this contrasts our designation of the two infected states (see pages 5
and 6), but one can easily see that the two states are essentially the
same as (T*) - Land (T**) - T* with our model's state values represented in parentheses. Perelson's new kinetic model is proposed
as follows:

=

(12)

dJt*

(13)

dft =

kVT + aL - 8T*,

jkVT - JLLL,

(14)
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(15)

dV
([[

f:
NuT*

pM*

cV.

In this model, all variables T, T*, M*, L, and V are functions
of time. The immune system's cytotoxic T cells or macrophages,
M, become infected at a rate constant kM and enter the long-lived
infected cell state, M*. These cells continuously produce virus at an
average rate per cell, pM*, and are lost at a death rate of -/tMM*.
Another assumption in this model is that when T cells are
infected, actively infected T* cells are generated with a rate constant k, and latently infected T cells harboring viral information in
their genome (total DNA) are generated with a rate constant jk,
smaller by a factor of j. The growth of the latently infected T cells
is modeled by equation (13), and they have a death rate of -8L L
and a rate -aL of transformation into actively infected T* cells.
The combination of the two rates of removal corresponds to a combination removal rate constant of -/tL = -a - 8L . In equation (12),
T* are lost with a removal rate of -8 and produce a total of N viral
particles in the course of their infected lifetime. In the last ODE
(15), virions, V, are cleared at a rate -cV.
This model, like ours, was used to obtain an optimal combination of chemotherapies. The cocktail treatment included a protease inhibitor and two reverse transcriptase inhibitors [15].
Clearly, there is not only one correct way to model the HIV
infection process. Our model may account for longer treatment periods and different infective states of the T cells, but it does not
model the activity of the virus in other regions of the body. In some
cases, such as when the patient exhibits AIDS related dementia, a
more flexible model should be used, eg., one that models neuronal
infection in the brain. Due to different initial assumptions, each
model may be justifiable in different situations. Our treatment situation may neglect the presence of other compartments in the body
susceptible to HIV infection, but it does take into account the latent
and active states of T cell infection and more thoroughly describes
the interaction between virus and healthy T cell.
Having a more complicated model does not necessarily mean
having a better model. It is entirely up to the medical researcher
to decide which variables he or she wishes to neglect in an optimal
treatment schedule for a patient. Our model, equations (1 )-( 4), will
12

soon be modified with chemotherapy terms and will be used as structural support for the objective function we seek to maximize. One
should keep in mind that the following procedures may be initiated
for the other models stated above. Before commenting on the modifications made in our model to include dual chemotherapies, the
theory behind optimal control will briefly be explained. For more
information on the existence and application optimal control, please
refer to [7] and [12].
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3.1

Optimal Control
Introduction to Optimal Control Theory

Optimal control theory is a method used to solve for an extremum
value of an objective functional involving dynamic variables. This
maximizing or minimizing process is accomplished by adjusting the
control variable, u, until the maximum or minimum is achieved.
The control which yields the extreme value is denoted by u* and is
called an optimal control. This control variable, which in our case
is a function of time, can be used in many modeling situations and
could be a function of any controlable variable, i.e. if one could
directly manipulate the number of viruses, the u could be V.
If the mathematical model consists of PDE's (partial differential equations), the control will exhibit its action on infinite
dimensional systems. In our case however, we use a deterministic
control of a finite dimensional system in time, and the states of
infection are described by ODE's. The variables are divided into
two classes: state variables and control variables, both of which are
functions of time in our model. The movement of state variables of
infection is governed by first order ODE's, and the control affects
the behavior of the ODE's in some way. The maximum principle
developed by L.S. Pontryagin in the late 1950's gives a method to
find the optimal control [7].

3.2

Our Objective

Our control, u(t), represents an effective chemotherapy dosage bounded
between 0.0% and 100.0%, or u(t) E [0,1] where u ranges from no
chemotherapy (0.0) to a maximum dosage (1.0). In this problem, the
primary goal is to maximize the healthy T cell count of an HIV infected patient, and the secondary aim is to minimize any side effects
caused by the chemotherapy control. Thus, the problem is to find
the optimal chemotherapy percentage, u( t), throughout the length
of treatment to ~ t ~ t f. This optimal control should maximize
our objective, i.e., it should maximize both the healthy T cell concentration, T(t), and the negative value representing side effects,
which is denoted by _~Bu2(t). In the side effects term, the ~B
represents a balancing (B) constant which relates the percentage of
chemotherapy in a meaningful way to the healthy T cell concentra14

tion. Both the T cell concentration and side effects of chemotherapy
are included in the objective functional, J(u). By definition [12], a
functional maps functions into numbers. In our case, the functional
J (u) is an integral over the treatment time. Therefore, a control
u(t) is sought to maximize the objective functional J(u) in equation

(16):
(16)

If we apply two different control chemotherapies Ul (t) and
U2(t), the problem is very similar except that the functional J(UI, U2)
will be maximized with respect to both controls. The new objective
functional is stated in equation (17), and takes into account the side
effects of combination chemotherapy:
(17)

One can easily imagine implementing many more controls by
simply tacking on each one's side effects to our objective functional.
In both equations (16) and (17), chemotherapy benefits a patient
by increasing the healthy T cell population, T(t), which is described
by ODE (1) in our system. There also exists a certain 'cost' on the
patient for administering a chemotherapy, and this cost represents
the potential for harmful side effects from each drug. These side
effects are taken into account by the balancing constants Bi for
the control chemotherapy Ui. Each balancing term balances the
systemic cost of its respective chemotherapy to the benefit measured
in healthy T cell concentration.
Although a consensus on the apparent costliness of chemotherapy does not yet exist, the solution of the maximum of J was pursued
with an adjustable value for each B. Practicing physicians using this
study should weigh the apparent side effects of each drug administered to the patient and proceed according to the optimal treatment
15

schedule generated by the following analysis. The solutions and effects of two optimal chemotherapies will now be implemented in our
model.

3.3

The Modified Model

The optimal control used in this problem represents the percentage
of the effect a chemotherapy has on inhibiting the virus. As stated
before, each control Ui(t) is bounded on the interval [0,1] where
U
0 implies no chemotherapy and U = 1 indicates maximum
chemotherapy. Our control class consists of measurable functions
defined on a limited window of treatment time [to, tf]. This treatment period is limited in order to lessen the effects of resistance or
side effects on the immediate state of the model. Since HIV has an
extremely high rate of mutation, a portion of the viral population
may develop resistance to a chemotherapy treatment after some finite amount of time. This necessitates a finite interval of treatment
since the ineffective drug can still exhibit side effects.
Previous work has already been done with controls which decreased viral load by multiplying the parameter N in equation (4)
by the chemotherapy control representing a reverse transcriptase
inhibitor [9, 16]. In our model, a similar type of control was used
as well as another which inhibited the interaction between virus
and T cell. The objective function used was essentially equation
(17). The first control Ul (t) represents an inhibitory drug used
to block viral binding to the T cell. This control is analogous to
a chemokine-like substance which competitively or irreversibly inhibits a secondary receptor on a T cell required for HIV entry, for
example the chemokine receptor CXCR4 [13]. Since Ul (t) blocks
binding, it is attached to the term kl VT in both equations (1) and
(2), but not equation (4). By applying the control in the manner of
(1- ul(t))kl VT, the virus to T cell interaction is multiplied by zero
if our control is at its maximum dosage of Ul(t) = 1. If however,
the chemotherapy is absent (Le. Ul(t) = 0), complete interaction at
a rate kl will resume in the system.
The second control used in the model is denoted by U2(t).
This control represents a viral protease inhibitor or any other chemical (such as AZT, ddC, etc) which decreases viral production from
an actively infected host cell. As in the case of our first control, this
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chemotherapy will be applied as (1 U2(t)). Instead of inhibiting
virus to T cell interaction, U2 affects the amount (N) of correctly
processed virus budding from a T** cell. This control is applied in
equation (4) in our system of equations.
After applying both controls to our model, the system of
equations is altered as follows, with the control terms in bold type:

~V -

(18)

¥t

1

(19)

([t

dT*

= (1 -

(20)

dT**
dt -- k2 T* -

Ul

JlTT

rT( 1 - T + E~ TOO) - (1 - ul(t))kJ VT,

(t) )kl VT
II.

/LT T * - k2T*,

T**

f"'b,

(21)
Now that the model has been modified to include two different controls, the optimization process can begin. Our goal, as
stated previously, is to characterize the optimal controls ui (t) and
u;(t) satisfying the maximum of the objective functional (17). The
existence of an optimal control may be found in Fleming and Rishel
[6]. In this problem, the necessary concavity of J(ui, u;) holds, and
therefore the required conditions of Pontryagin's Maximum Principle have been met.
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4
4.1

Solving the Optimal Control Problem
Setting up the Maximum Problem

In order to set up this maximization problem, the system of ODE's
(equations (18-21)) must first be attached to the objective functional
(equation (17)). This is accomplished by using the Lagrangian function, equation (22), with penalty terms attached for the bounds on
the controls. For our problem, the Lagrangian is the integrand of
the objective functional J(Ul' U2), equation (17), coupled with the
state ODE's by means of functions known as adjoints, each of which
is denoted by Ai(t) corresponding to the ith state. The penalty
terms are denoted by Wi(t) with Wi(t) 2 0 for i = 1,2,3,4, and dd~i
denotes the right hand side of each ODE in our system, for states
Si = T, T*, T**, V from equations (18-21). The Lagrangian, L, is:
(22)

L

= {T(t) -

+Al

dT

dI

+Wl ( Ul

+

~BIUI(t) - ~B2U~(t) }
dT*

A2---a:t

(t))

+

+

W2 (1

dT**

A3([t

+

(t))

+

Ul

dV

A4 dt

W3 (U2 (t))

+

W4 (1

U2 (t)) .

Since our problem contains bounded controls 0 ::; Ul, U2 ::;
1, we made use of penalty multipliers, Wi, representing functions
of time. These Wi'S are used to attach our control constraints.
The penalty multi pliers satisfy Wl ( Ul ( t)) = 0, W2 (1 - Ul (t) )
0,
W3(U2(t)) = 0, and w4(1 - U2(t)) = 0 on Ub U2 E (0,1), with the
additional constraint Wi 2 0 for all i. The penalty terms act to keep
each control bounded in the interval [0, 1]. By Pontryagin's Maximum Principle, the Lagrangian is maximized with respect to Ul, U2
at ut, u2 when the Lagrangian is evaluated at the optimal states and
adjoints.
Since we will now be maximizing the Lagrangian function
with respect to each u, we must choose controls which are bounded
on [0, 1]. In order to see this, consider what would happen to the
penalty terms if either U < O. This choice of a control would cause
the terms Wl(Ul(t)) and W3(U2(t)) to become negative and pull the
Lagrangian function down and way from the maximum. Therefore
negative values of U would not be chosen as controls for a maximum
18

L value. The same idea holds whenever our control escapes its
upper bound of 1, again causing the Lagrangian to decrease and not
attain its absolute maximum. Clearly, the only values which can
maximize L are those between 0 and 1. The penalty terms will soon
be implemented in order to put bounds on the optimal solution in
section 4.3.

4.2

Adjoint Conditions

In order to attach the system of ODE's onto the objective function,
adjoint functions were used. Pontryagin's maximum principle gives
the necessary conditions that the adjoint functions must satisfy. The
differential equation satisfied by the ith adjoint function, derived in
reference [7], is the following:

where i

= 1,2,3,4 and Si = T, T*, T**, V.

The adjoints have the following boundary conditions at the final
time of treatment, tr
i

= 1,2,3,4.

As one can easily see, there are as many adjoints as there are
state equations, and the adjoint .Ai corresponds to the ith state variable. Now, another difficulty has been introduced into the problem.
Not only must four more first order ODE's be solved, but these adjoint ODE's have final conditions as opposed to the initial conditions
of the state ODE's. This creates a problem in the iterative solving
program which will be explained later in the following paragraphs.
The ODE's describing the rate of change of each adjoint with respect
to time will now be presented. Differentiating the Lagrangian (22)
with respect to each state variable by the ith generating condition
above gives the following equations:
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(23)

~

-1 + AI(!1T - r

-A2(1 - ul)k t V

l:-: T") +

+ r( 2T +

(1 - uI)k l V)

+ A4kl V,

f!;,x) + A2(!1T + k2) - Aa k2,

(24)

~

Al (

(25)

~

Al

(26)

dA4
dt

Al (1 - ul)k1T - A2(1 - ut)ktT + A4(kt T

(f!;,x) + Aa!1b - A4(N!1b(1- U2)),
+ Jlv).

For the untreated case (no controls), these adjoints are not
needed and the iterative algorithm Runge-Kutta [2] may be used to
solve the system of four state equations forward in time. Once formulas were obtained for the optimal controls (see next section), the
solving program was implemented to find the solution values during
the treatment of an HIV infected patient. In order to solve for our
optimal controls, a method commonly used in Calculus (differentiation with respect to each control) was generalized for finding the
maximum value of the Lagrangian's curve where the first derivative
equals zero.
Each of the adjoint ODE's has a boundary condition of zero
at the final time of treatment, t f. This creates a problem in developing an iterative solver. Not only must the first four coupled ODE's
(18-21) be solved forward in time from initial conditions, but also
the second system of adjoint ODE's (23-26) must be solved backward in time from their final conditions. The program would be a
lot easier to implement if the ODE's were uncoupled, i.e., if they
did not depend on one another, because then a simple Runge-Kutta
program could solve the state ODE's forward in time, and a separate loop could walk the adjoint ODE's backward in time. However,
these two systems of four ODE's present a unique problem in that
they are coupled to each other, and therefore the two systems must
be solved simultaneously.
A unique program was developed specifically for this need,
and it iteratively solves the ODE systems by first guessing values
20

..
for the adjoints at all time t E [to, t f). These guesses were then
used to solve the state ODE system which, in turn, yielded values
for each state T, T* 1 T**, and V at time t. These state values were
then plugged into the adjoint system which was subsequently solved
using the Runge-Kutta method of order four backward in time from
tf·

After each run through the algorithm, the convergence was
tested by comparing the absolute error between each state value at
run k and the previous state value at run k 1. If the difference
between the two values was greater than a specified tolerance, E,
the newly generated adjoints from run k were cycled through the
initial loop in place of the adjoint guesses. If however, the error was
less than the specified tolerance, the iterative solve was terminated
and the state data at t E [to, t f] was collected and placed in a matrix. This matrix was subsequently exported to MATLAB4.2c, and
graphs of the various states and controls versus time were obtained.

4.3

The Optimality Condition

The Lagrangian is maximized with respect to both U1 and U2 separately in order to obtain the optimal value of ui and u 2. At both
of these control values, the maximum Lagrangian is obtained. The
derivative of the Lagrangian with respect to both ui and u 2 is thus
zero, since at the absolute maximum the slope of a function is zero.
First, partially differentiating our L with respect to U1 yields:

which can then be solved for our optimal

ui,

giving us:

* _ (AI - A2)k1VT+W1 - W2
u1 E1
.

Thus, from the conditions on our penalty multipliers,
following expression may be obtained:

(27)

uj = Min ( MaX(*l,O),l),
where *1

(AI - A2)k1VT
B1
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Wi

2:: 0, the

In order to obtain an expression for our second optimal control, U 2,
the same method will be followed. This second analysis will proceed
step-by-step. As before, the derivative of L with respect to U2 is set
equal to zero, giving us:

which can then be solved for u 2 as follows:

In order to eliminate the unknown penalty functions, consider
3 disjoint and exhaustive cases on the optimal control:
• Case (i) On the set {t I 0 < u 2(t) < I}, we may set W3(t)
W4(t) = 0, hence generating the optimal control,

• Case (ii) On the set {t
therefore giving us:

=

I u 2(t) = I}, W3(t) = 0 and W4(t) 2: 0,

which implies
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• Case (iii) On the set .{t I u;(t)
which gives us the relation:

u;(t)

o=

= OJ, w3(t)

-A4 N ftb T **
B2

~ 0 and

W4(t) = 0,

+ W3 >

-A4 N ftb T **
B2

From this expression, our solution for the third case is obtained:

Now the reader can more easily see how the condition for
equation (28) is generated:
(28)
where

*2

= - >.. 4 NB~bT**
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u;

in

Discussion of

5
5.1

~esults

and Conclusions

The Results

The analysis is now complete. The equations for each optimal control have been obtained and have been implemented into a program
which iteratively solves both systems of equations. Equations describing the HIV infected scenario have been implen1ented with dual
chemotherapy - one, a chemokine-like derivative that inhibits binding (un and the other being that of a viral protease inhibitor that
inhibits correct protein processing of new virions (u 2). Both of these
optimal controls represent solution curves for an optimal treatment
schedule. Through a computational algorithm including both forward and backward Runge-Kutta, we were able to numerically solve
the two systems of ODE's, the state system and the adjoint system.
The figures on the following pages are presented for perception of the process of infection, the optimal treatment schedule, and
the effects that the optimal controls have on an HIV positive patient. Although the model without controls has been verified, the
effect of this optimal combination treatment has not yet been shown
to mimic our data. However, the methods which were used to attain the optimal chemotherapy schedule has been verified previously
[2, 6, 7], and research suggests that these optimal treatment schedules are the true solution for this problem.
The following is a description of each of the figures, all of
which were produced using MATLAB:

• FIGURE 1: The optimal treatment schedule of ui(t),
Bl = 50, interval 100 days:
Figure 1 represents the optimal 100 day treatment schedule for
the first chemotherapy, ui - a chemokine-like binding inhibitor
with Bl
50. % chemotherapy is plotted on the y-axis, and
the number of days is on the x-axis .

• FIGURE 2: The optimal treatment schedule of u 2(t),
B2 = 400, interval 100 days:
Figure 2 represents the optimal 100 day treatment schedule
for the second chemotherapy, u2* - a protease inhibitor with
B2 400.
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• FIG1JRE 3: The optimal treatment schedule of both
u;:(t) and u2(t), with Bl 50 and B2 = 400, 350, 250, and
150:
Figure 3 consists of four separate graphs, each containing solution curves of Ul in a solid line and U2 in a dashed line. As
we decrease the cost of U2 from 400 to 150, the length of time
of maximal U2 treatment increases from about 27 days to 67
days, while the Ul treatment decreases proportionally.

• FIGURE 4: T cell behavior, with and without optimal
combination treatment for two sequential intervals of
100 days:
The solid line represents healthy T cell behavior during HIV infection, while the dashed line represents what would happen to
the T cell population given optimal combination chemotherapy
for two successive 100 day intervals starting at day 900.

• FIGURE 5: HIV behavior, with and without optimal
combination treatment for two sequential intervals of
100 days:
The solid line represents viral behavior during infection, while
the dashed line indicates viral population changes under optimal combination treatment for two successive 100 day intervals
beginning at day 900.

• PRINTOUT:
This printout contains the Fortran program used to solve our
optimal control problem. The data generated from the program
was plotted using MATLAB.

5.2

Future Analysis

Although anti-HIV treatment does slow the progression of the disease in HIV infected patients, much uncertainty exists about how
to best administer the drug during the treatment period. Through
this analysis, an optimal treatment schedule is put forward, to maxinlize a patient's healthy T cell count while also keeping track of
potential side effects of each chemotherapy. When a new drug has
25

passed FDA guidelines and has been tested through clinical trials,
the maximum percentage dosage can be obtained and side effects
will be recorded. After relating the side effects to the balancing
constant in the objective equation, J(Ul' U2, ... ), one can then solve
for an optimal treatment schedule which can serve as a guideline for
HIV infected patients to follow.
The unique numerical algorithm developed to solve this problem will serve as a template for future applications in the medicinal
treatment of HIV infection. With new combinations of chemotherapies being developed, one can imagine the usefulness of such a computer program. Mathematical modeling of HIV infection and solutions of optimal control may serve as a stepping stone between clinical medical research trials and actual implementation of the drug
regiment throughout the HIV infected population. Truly, mathematics does have a place in the medical field today.
Other interesting studies would make use of modifications
to the structure of our model. For example, one could check the
reliability of the parameters by setting each as a function of time and
performing a sensitivity analysis on them. Most seem to have one
or two significant digits, and therefore they could vary significantly,
i.e. .02 could vary from .015 to .024. Checking the sensitivity by
perturbing each parameter would be useful in verifying the stability
of this model.
Special thanks to Dr. Suzanne Lenhart, Dr. Renee Fister,
Dr. Charles Collins, Dr. Raj Pal Soni, and Rick Moran, without
whom none of this would have been possible.
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IMPLICIT NONE
REAL B,B2,H,ICX(4),FCY,KX(4,4) ,KY(4,4),X(4,lOOl)
REAL XN(4,lOOl) ,Y(4,lOOl) ,YN(4,lOOl) ,T,T1,T2,V,Y1,Y2,Y3,Y4
REAL U1(1001) ,U2(1001) ,EPSI,SUM,TI,TF,X1,X2,X3,X4,Zl,Z2,Z3,Z4
INTEGER I,N,M,K,P,COUNTER,Z
X1(T,T1,T2,V,U1)=
!10/(1+V)-.02*T+.03*T*(1-(T+T1+T2)/1500)-2.4E-5*(1-U1)*V*T
X2(T,T1,V,U1)=2.4E-5*(1-U1)*V*T-(.02+.003)*T1
X3 (T1,T2) .003*T1-.24*T2
X4(T,T2,V,U2)=(1-U2)*1200*.24*T2-2.4E-5*V*T-2.4*V

.,c Watch out for the 2.4's above and below, some should be 2.4*10A 5 etc ...

!

Zl(Y1,Y2,Y4,T,T1,T2,V,U1)=
!-1+Y1*(.02 .03+.03*(2*T+T1+T2)/1500+
!2.4E-5*(1-U1)*V)-2.4E-5*V*(Y2*(1-U1)-Y4)
Z2(Y1,Y2,Y3,T)=(Y1*.03*T)/1500+.023*Y2 .003*Y3
Z3(Y1,Y3,Y4,U2)=Y1*(.03*T)/1500+.24*(Y3-(1-U2)*1200*Y4)
Z4(Y1,Y2,Y4,T,V,U1)=
!Y1*(10/«1+V)**2)+2.4E-5*T*(1-U1))-Y2*2.4E-5*(1-U1)*T+
!Y4*(2.4E-5*T+2.4)
COUNTER=O
TI 0.0
TF=lOO.O
N=lOOO
M=lOOl
H=(TF-TI)/N
FCY=O.O
EPSI=.Ol
Z=2
B=.50E2
B2=4.0E2
ICX(1)=874.022
ICX(3) 1.51225E-02
ICX(2) 1.10754
ICX(4) .566098

...

....

XN(l,l)=ICX(l)
XN(2,1)=ICX(2)
XN(3,l)=ICX(3)
XN(4,l) ICX(4)

WI'

.,

.....

· C This is the initial guess for the 4 adjoint eqns

....
....

DO P=l,4
DO I=l,M
Y(P,I)=l.O
END DO
END DO

....,
C

·C
.,.C

.., C
..,

.,. 57
WI'

....
....

....
WI'

The next step is the start of the MAjor
! !
MAybe use a GO TO statement at the end of the loops to the line directly below
Y(l) is the initial condition, all the way to Y(lOl) which is Y at time
2
The next loop is to find ICU (U(l))and all other U values
DO I=l,M
IF (2.4E-5*XN(4,I)*XN(l,I)*(Y(1,I)-Y(2,I))/B.GT.0.AND .
!2.4E-5*XN(4,I)*XN(1,I)*(Y(l,I)-Y(2,I))/B.LT.1) THEN
U1(I)=2.4E-5*XN(4,I)*XN(l,I)*(Y(1,I)-Y(2,I) )/B
ELSE
IF(2.4E-5*XN(4,I)*XN(1,I)*(Y(1/I)-Y(2,I) )/B.LE.O) THEN
U1 (I) 0.0
ELSE
U1(I)=1.0
END IF

END IF
IF (-Y(4,I)*1200*.24*XN(3,I)/B2.GT.O.AND.
!-Y(4,I)*1200*.24*XN(3,I)/B2.LT.1) THEN
U2(I)=-Y(4,I)*1200*.24*XN(3,I)/B2
ELSE
IF(-Y(4,I)*1200*.24*XN(3,I)/B2.LE.O) THEN
U2(I)=O.O
ELSE
U2(I)=1.0
END IF
END IF
IF

(I.EQ.M) THEN
GO TO 123
ELSE
END IF
KX(1,1)=H*X1(XN(1,I)
KX(2,1)=H*X2(XN(1,I)
KX(3,1)=H*X3(XN(2,I)
KX(4,1)=H*X4(XN(1,I)

,XN(2,I) ,XN(3,I) ,XN(4,I) ,U1(I))
,XN(2,I) ,XN(4,I) ,U1(I))
,XN(3,I))
,XN(3,I) ,XN(4,I) ,U2(I))

KX(1,2)=H*X1(XN(1,I)+KX(1,1)/2,XN(2,I)+KX(2,1)/2,XN(3,I)+
!KX(3,1)/2,XN(4,I)+KX(4,1)/2, (U1(I+1)+U1(I))/2)
KX(2,2)=H*X2(XN(1,I)+KX(1,1)/2,XN(2,I)+KX(2,1)/2,XN(4,I)+
! KX ( 4 , 1) 12, (U1 ( I + 1 ) + U1 (I) ) 12 )
KX(3,2)=H*X3(XN(2,I)+KX(2,1)/2,XN(3,I)+KX(3,1)/2)
KX(4,2)=H*X4(XN(1,I)+KX(1,1)/2,XN(3,I)+KX(3,1)/2,XN(4,I)+
! KX (4 , 1) 12, (U2 ( I + 1) + U2 (I) ) 12)
KX(l,3)=H*X1(XN(l,I)+KX(1,2)/2,XN(2,I)+KX(2,2)/2,XN(3,I)+
!KX(3,2)/2,XN(4,I)+KX(4,2)/2, (U1(I+1)+U1(I))/2)
KX(2,3)=H*X2(XN(1,I)+KX(1,2)/2,XN(2,I)+KX(2,2)/2,XN(4,I)+
! KX ( 4 , 2 ) 12, (U 1 ( I + 1 ) + U1 ( I) ) 12 )
KX(3,3)=H*X3(XN(2,I)+KX(2,2)/2,XN(3,I)+KX(3,2)/2)
KX(4,3)=H*X4(XN(1,I)+KX(1,2)/2,XN(3,I)+KX(3,2)/2,XN(4,I)+
! KX ( 4 , 2 ) 12, (U2 ( I + 1) + U2 (I) ) 12)
KX(1,4)=H*X1(XN(1,I)+KX(1,3) ,XN(2,I)+KX(2,3) ,XN(3,I)+
!KX(3,3) ,XN(4,I)+KX(4,3) ,U1(I+1))
KX(2,4)=H*X2(XN(1,I)+KX(1,3) ,XN(2,I)+KX(2,3) ,XN(4,I)+
!KX(4,3) ,U1(I+1))
KX(3,4)=H*X3(XN(2,I)+KX(2,3) ,XN(3,I)+KX(3,3))
KX(4,4)=H*X4(XN(1,I)+KX(1,3) ,XN(3,I)+KX(3,3) ,XN(4,I)+
!KX(4,3) ,U2(I+l))

~c

Walk the T,T*,T**,

and the V eqns here!!!

XN(l,I+l)=XN(1,I)+(KX(1,1)+2*KX(1,2)+2*KX(1,3)+KX(1,4) )/6.
XN(2,I+1)=XN(2,I)+(KX(2,1)+2*KX(2,2)+2*KX(2,3)+KX(2,4))16.
XN(3,I+1)=XN(3,I)+(KX(3,1)+2*KX(3,2)+2*KX(3,3)+KX(3,4))16.
XN(4,I+1)=XN(4,I)+(KX(4,l)+2*KX(4,2)+2*KX(4,3)+KX(4,4) )/6.
123

END DO

C Now work from final time to initial time!
C Given the guess on Y's, we got the X's,
~C now we have to work
C backwards to see if i t ' s correct! The next small loop is to initialize
<W'C the X() values for the first time through only
<W'

IF (Z.EQ.2)
DO P=1,4

THEN

DO I=1,M
X(P,I)=XN(P,I)
END DO
END DO
Z=O
ELSE
END IF
~

C Next work backwards ..
DO P=1,4
YN(P,M)=FCY
END DO

~C

NOW we must walk the 4 adjoints

~

....

(JUST the Y eqns!)

DO I=1,N
K=2+N-I

WI"

,.,

...

....

.,.

...
...
.,.

...
...
...

KY(1,1)=H*Z1(YN(1,K) ,YN(2,K)
!XN(4,K) ,U1 (K))
KY(2,1)=H*Z2(YN(1,K),YN(2,K)
KY(3,1)=H*Z3(YN(1,K),YN(3,K)
KY(4,1)=H*Z4(YN(1,K) ,YN(2,K)

,YN(4,K) ,XN(1,K),XN(2,K) ,XN(3,K),
,YN(3,K) ,XN(1,K))
,YN(4,K) ,U2(K))
,YN(4,K) ,XN(1,K),XN(4,K) ,U1(K)

KY(1,2)=H*Z1(YN(1,K)-KY(1,1)/2,YN(2,K)-KY(2,1)/2,YN(4, K)!KY(4,1)/2, (XN(1,K-1)+XN(1,K))/2, (XN(2,K-1)+XN(2,K))/2, (XN(3,K-1)+
!XN(3,K))/2, (XN(4,K-1)+XN(4,K) )/2, (U1(K-1)+U1(K))/2)
KY(2,2)=H*Z2(YN(1,K)-KY(1,1)/2,YN(2,K)-KY(2,1)/2,YN(3, K)
!KY(3,1)/2, (XN(1,K-1)+XN(1,K))/2)
KY(3,2)=H*Z3(YN(1,K)-KY(1,1)/2,YN(3,K)-KY(3,1)/2,YN(4, K)! KY (4 , 1) 12, (U2 (K-1) +U2 (K) ) 12)
KY(4,2)=H*Z4(YN(1,K)-KY(1,1)/2,YN(2,K)-KY(2,1)/2,YN(4, K)! KY ( 4 , 1) 1 2, (XN ( 1 , K-1 ) + XN ( 1, K) ) 1 2, (XN ( 4 , K-1 ) + XN ( 4 , K) ) 1 2, (U 1 (K -1 ) +
! U1 (K) ) 12)
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....

.,
..,
WI"

KY(1,3)=H*Z1(YN(1,K)-KY(1,2)/2,YN(2,K)-KY(2,2)/2,YN(4,K )
!KY(4,2)/2, (XN(1,K-1)+XN(1,K))/2, (XN(2,K-1)+XN(2,K))/2, (XN(3,K-1)+
!XN(3,K) )/2, (XN(4,K-1)+XN(4,K))/2, (U1(K-1)+U1(K))/2)
KY(2,3)=H*Z2(YN(1,K)-KY(1,2)/2,YN(2,K)-KY(2,2)/2,YN(3, K)! KY ( 3 , 2) 1 2, (XN ( 1 , K-1 ) + XN ( 1 , K) ) 1 2 )
KY(3,3)=H*Z3(YN(1,K)-KY(1,2)/2,YN(3,K)-KY(3,2)/2,YN(4, K)
! KY ( 4 , 2 ) 12, (U2 (K -1 ) + U2 (K) ) 12 )
KY(4,3)=H*Z4(YN(1,K)-KY(1,2)/2,YN(2,K)-KY(2,2)/2,YN(4, K)!KY(4,2)/2, (XN(1,K-1)+XN(1,K))/2, (XN(4,K-1)+XN(4,K))/2, (U1(K-1)+
! U1 (K) ) 12)

KY(1,4)=H*Z1(YN(1,K)-KY(1,3) ,YN(2,K)-KY(2,3)
!KY(4,3) ,XN(1,K-1) ,XN(2,K-1) ,XN(3,K-1) ,XN(4,K-1)
KY(2,4)=H*Z2(YN(1,K)-KY(1,3) ,YN(2,K)-KY(2,3)
!KY(3,3) ,XN(1,K-1))
KY(3,4)=H*Z3(YN(1,K)-KY(1,3) ,YN(3,K)-KY(3,3)
! KY ( 4 , 3) , U2 (K -1) )
KY(4,4)=H*Z4(YN(1,K)-KY(1,3) ,YN(2,K)-KY(2,3)
!KY(4,3) ,XN(1,K-1) ,XN(4,K-1) ,U1(K-1»)

,YN(4,K),U1(K-1))
,YN(3,K)
,YN(4,K)
,YN(4,K)-

YN(1,K-1)=YN(1,K)-(KY(1,1)+2*KY(1,2)+2*KY(1,3)+KY(1,4) )/6 .
YN(2,K-1)=YN(2,K) (KY(2,1)+2*KY(2,2)+2*KY(2,3)+KY(2,4))/6 .
YN ( 3 , K-1 ) = YN ( 3 , K) ( KY ( 3 1 ) + 2 * KY ( 3 , 2 ) + 2 * KY ( 3 , 3 ) + KY (3 , 4) ) 1 6 .
YN(4,K-1)=YN(4,K) (KY(4,1)+2*KY(4,2)+2*KY(4,3)+KY(4,4) )/6 .
I

END DO
C Now the test for convergence ...
SUM 0.0
DO P=1,4
DO I=l,M
SUM=SUM+ABS(YN(P,I)-Y(P,I) )+ABS(XN(P,I)-X(P,I))
END DO
END DO
IF (SUM.GT.EPSI) THEN
DO P=l,4
DO I=l,M
Y(P,I)=YN(P,I)
X(P,I)=XN(P,I)
END DO
END DO
COUNTER=COUNTER+l
IF(COUNTER.GE.IOOO) THEN
PRINT*, 'NO convergence!!'
STOP
ELSE
GO TO 57
END IF
ELSE
END IF
DO I=l,M
PRINT*, H*(I-l) ,XN(l,I) ,XN(4,I),Ul(I) ,U2(I)
END DO
PRINT*, XN(2,lOl) ,XN(3,lOl)
END

6
Bl
s

Table of ParaII).eters
= 50

10

mm -3, B2

400

mm -3 balancing constants

days-lmm- 3 , a linear growth rate constant

.02 days-I, a death rate constant for both healthy and latently infected T cells
/-LT

r = .03
Tmax

days-I, a logistic growth rate constant

= 1500 mm- 3 , the maximum number of T cells (healthy and

infected) per mm3

kl = 2.4 X 10- 5 mm3 days-l, a rate constant for the infective interaction of viral particles and T cells
k2 .003 days-I, a rate constant describing the transfer of T cells
from the latently infected state T* to an actively infected state T**
days-I, a death rate constant for actively infected T cells,
or equivalently a birthing rate for the HIV virus
/-Lb = .24

N

1200, the number of viral particles produced per dying T cell

/-Lv = 2.4

days-I, a death rate constant for the HIV virus
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